<DOC>
	<DOCNO>NCT00850499</DOCNO>
	<brief_summary>This randomize , open-label , active-control , multicenter Phase 2 study VELCADE+fludarabine comparison rituximab+fludarabine subject relapse advanced follicular lymphoma . Eligible subject randomize 1:1 ratio 2 treatment arm ( 55 subject per arm ) .</brief_summary>
	<brief_title>Phase 2 Study VELCADE With Fludarabine Comparison Rituximab With Fludarabine Follicular Lymphoma Patients Previously Treated With Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Male female subject 18 year old Histologically proven diagnosis follicular nonHodgkin 's lymphoma grade 1or 2 accord World Health Organization classification Subjects must receive least 12 dos ( 375mg/m2 appropriately adjust dose ) rituximab treatment lymphoma single agent rituximab rituximabcontaining regimen document subject 's medical record Documented relapse progression follow last antineoplastic treatment At least 1 measurable tumor mass ( ≥1.5 cm x ≥1.0 cm ) Subjects histological clinical transformation aggressive lymphoma prior treatment VELCADE fludarabine . antineoplastic ( include unconjugated therapeutic antibody ) , experimental , radiation therapy within 3 week randomization nitrosoureas within 6 week randomization radioimmunoconjugates toxin immunoconjugates within 10 week randomization major surgery within 3 week randomization chronic use corticosteroid , dexamethasone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>